Context Therapeutics Inc.
Qualité des données : 83%
CNTX
NASDAQ
Manufacturing
Chemicals
2,49 €
▼
0,10 €
(-3,86%)
Cap. Boursière: 240,72 M
Prix
2,62 €
Cap. Boursière
240,72 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—
Quick Summary
Points Clés
Negative free cash flow of -26,42 M
Croissance
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Qualité
Return on Equity
-46,40%
Au-dessus de la moyenne du secteur (-54,47%)
ROIC-40,27%
Net MarginN/A
Op. MarginN/A
Sécurité
Debt / Equity
N/A
Current Ratio13,10
Interest CoverageN/A
Valorisation
PE (TTM|NTM)
-6,66 | -5,38
En dessous de la moyenne du secteur (-1,49)
P/B Ratio3,29
EV/EBITDAN/A
Dividend YieldN/A
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1385 pairs)
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1385 pairs)| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | -6,7 | -1,5 |
| P/B | 3,3 | 1,6 |
| ROE % | -46,4 | -54,5 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
Objectif de Cours des Analystes
8 analystes
Buy
Actuel
2,49 €
Objectif
6,00 €
4,00 €
5,50 €
9,00 €
Prévisions
P/E Prévisionnel
-5,38
BPA Prévisionnel
-0,46 €
CA Est.
0,0
Estimations de Bénéfices
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| FY2027 |
-0,46 €
-0,65 € – -0,25 €
|
0,0 | 8 |
| FY2026 |
-0,47 €
-0,62 € – -0,21 €
|
0,0 | 9 |
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| 2026 Q2 |
-0,11 €
-0,15 € – -0,06 €
|
0,0 | 9 |
| 2026 Q1 |
-0,12 €
-0,14 € – -0,06 €
|
0,0 | 9 |
Surprises de Résultats
Derniers 4 trimestres
| Trimestre | BPA Est. | BPA Réel | Surprise |
|---|---|---|---|
| Q42025 | -0,11 € | -0,14 € | -32,6% |
| Q32025 | -0,09 € | -0,10 € | -14,3% |
| Q22025 | -0,05 € | -0,09 € | -73,1% |
| Q12025 | -0,06 € | -0,05 € | +21,1% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -36,12 M |
| ROE | -46,40% | ROA | -43,42% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -26,42 M |
| ROIC | -40,27% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 13,10 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 73,02 M | Tangible Book Value | 73,17 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -6,66 | Forward P/E | -5,38 |
| P/B Ratio | 3,29 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -10,97% | ||
| Market Cap | 240,72 M | Enterprise Value | 163,79 M |
| Per Share | |||
| EPS (Diluted TTM) | -0,38 | Revenue / Share | N/A |
| FCF / Share | -0,29 | OCF / Share | -0,29 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 73,14% |
| SBC-Adj. FCF | -27,64 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -36,12 M | -26,73 M | -23,96 M | -14,84 M | -10,46 M |
| EPS (Diluted) | -0,38 | -0,46 | -1,50 | -0,93 | -3,69 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -39,70 M | -29,92 M | -25,07 M | -15,38 M | -10,53 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | — | — | — | — | — |
| SG&A Expenses | — | — | — | — | — |
| D&A | 16 251,0 | 10 881,0 | 12 044,0 | 9 268,0 | — |
| Interest Expense | — | — | 1,16 M | 547 268,0 | 64 240,0 |
| Income Tax | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 68,49 M | 98,13 M | 16,06 M | 37,97 M | 51,31 M |
| Total Liabilities | 8,02 M | 2,86 M | 4,19 M | 3,21 M | 3,03 M |
| Shareholders' Equity | 60,47 M | 95,27 M | 11,87 M | 34,76 M | 48,27 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 66,00 M | 94,43 M | 14,45 M | 35,50 M | 49,64 M |
| Current Assets | 68,35 M | 97,90 M | 16,05 M | 37,85 M | 51,26 M |
| Current Liabilities | 8,02 M | 2,75 M | 4,19 M | 3,21 M | 3,03 M |
{"event":"ticker_viewed","properties":{"ticker":"CNTX","listing_kind":"stock","pathname":"/stocks/cntx","exchange":"NASDAQ","country":"US"}}